Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2011

View Archived Issues

Sangamo BioSciences provides update on product pipeline

UCB claims new PI3K inhibitors

Ortho-McNeil-Janssen Pharma patents new gamma-secretase modulators

Helix BioPharma submits IND to FDA for first-in-human study of L-DOS47

New cannabinoid CB1 receptor antagonists presented by sanofi-aventis

Ferrer claims new melatonin MT1 receptor agonists

Studies investigate effects of intranasal oxytocin in schizophrenia, depression and autism

AM-095 displays antifibrotic activity in vivo

JTT-305 shows bone anabolic effects in vivo

HPRG-induced downregulation of PlGF shows anticancer potential

BIND Biosciences begins phase I study of BIND-014 in cancer

Topica begins enrollment in phase I/IIa luliconazole trial in onychomycosis

Ablynx reports follow-up data from phase I trial of ALX-0141

AstraZeneca and SCRI join to develop targeted anticancer agent

Concert Pharma claims new PDE4 inhibitors and TNF-alpha production suppressors

Allozyne completes phase Ia trial of AZ-01 for multiple sclerosis

New inhibitors of HCV NS5A developed at Enanta Pharma

Omthera reports bioavailability data from ECLIPSE trial of Epanova

Sumavel DosePro obtains marketing approval in Germany and U.K.

FDA issues positive feedback for design of phase III Davanat trial in colorectal cancer

Peregrine Pharma begins phase II bavituximab trial in hepatitis C

Enrollment begins in phase III trial of sapacitabine as front-line AML therapy

Antigenics becomes Agenus and expands product portfolio

BioMarin begins phase I/II trial of BMN-673 in genetically defined cancers

Curis selects CUDC-907 as development candidate for targeted cancer program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...